Tags

Type your tag names separated by a space and hit enter

Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Mov Disord. 2004 Aug; 19(8):937-42.MD

Abstract

We studied absorption, efficacy, and tolerability in Parkinson's disease (PD) of a new preparation of apomorphine included in a microemulsion and administered by transdermal route (Apo-MTD). Twenty-one PD patients were treated with levodopa plus oral dopamine-agonists (T0), with levodopa alone (T1), finally with levodopa plus Apo-MTD (T2). Apo-MTD provided therapeutic plasma levels for many hours, improved Unified Parkinson's Disease Rating Scale III scores, and reduced total duration of off periods compared to T0 and T1. We concluded that Apo-MTD is absorbed and demonstrates clinical efficacy and long action. Therefore, it seems a promising add-on treatment for uncontrolled prolonged off phases in PD patients, but chronic tolerability needs further study.

Authors+Show Affiliations

Divisione di Neurologia e Neuroriabilitazione, Osp. S. Giuseppe, IRCCS Istituto Auxologico Italiano, Piancavallo (VB), Italy. lorenzopriano@yahoo.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15300660

Citation

Priano, Lorenzo, et al. "Transdermal Apomorphine Permeation From Microemulsions: a New Treatment in Parkinson's Disease." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 19, no. 8, 2004, pp. 937-42.
Priano L, Albani G, Brioschi A, et al. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. Mov Disord. 2004;19(8):937-42.
Priano, L., Albani, G., Brioschi, A., Calderoni, S., Lopiano, L., Rizzone, M., Cavalli, R., Gasco, M. R., Scaglione, F., Fraschini, F., Bergamasco, B., & Mauro, A. (2004). Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society, 19(8), 937-42.
Priano L, et al. Transdermal Apomorphine Permeation From Microemulsions: a New Treatment in Parkinson's Disease. Mov Disord. 2004;19(8):937-42. PubMed PMID: 15300660.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. AU - Priano,Lorenzo, AU - Albani,Gianni, AU - Brioschi,Andrea, AU - Calderoni,Sara, AU - Lopiano,Leonardo, AU - Rizzone,Mario, AU - Cavalli,Roberta, AU - Gasco,Maria Rosa, AU - Scaglione,Francesco, AU - Fraschini,Franco, AU - Bergamasco,Bruno, AU - Mauro,Alessandro, PY - 2004/8/10/pubmed PY - 2004/12/21/medline PY - 2004/8/10/entrez SP - 937 EP - 42 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 19 IS - 8 N2 - We studied absorption, efficacy, and tolerability in Parkinson's disease (PD) of a new preparation of apomorphine included in a microemulsion and administered by transdermal route (Apo-MTD). Twenty-one PD patients were treated with levodopa plus oral dopamine-agonists (T0), with levodopa alone (T1), finally with levodopa plus Apo-MTD (T2). Apo-MTD provided therapeutic plasma levels for many hours, improved Unified Parkinson's Disease Rating Scale III scores, and reduced total duration of off periods compared to T0 and T1. We concluded that Apo-MTD is absorbed and demonstrates clinical efficacy and long action. Therefore, it seems a promising add-on treatment for uncontrolled prolonged off phases in PD patients, but chronic tolerability needs further study. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/15300660/Transdermal_apomorphine_permeation_from_microemulsions:_a_new_treatment_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/mds.20054 DB - PRIME DP - Unbound Medicine ER -